Long-acting Preparations in Substance Abuse Management: A Review and Update
- PMID: 23833336
- PMCID: PMC3701347
- DOI: 10.4103/0253-7176.112194
Long-acting Preparations in Substance Abuse Management: A Review and Update
Abstract
Many pharmacological approaches have been used in managing substance use disorders. Conventional pharmacological agents have relatively short durations of action which make them vulnerable to non-adherence and relapse to substance use disorder. To overcome this problem, long-acting preparations have been developed with the aim of reducing the frequency of use and hence improving adherence. This review takes a broad overview of the long-acting preparations available for the management of substance use disorders. The pharmacology, advantages and disadvantages of these preparations are discussed. Many of these preparations hold promise for improving patient outcomes.
Keywords: Depots; implants; long acting preparations; pharmacoprophylaxis; substance use disorders.
Conflict of interest statement
Similar articles
-
Long-Acting Injectables: Current Perspectives and Future Promise.Crit Rev Ther Drug Carrier Syst. 2019;36(2):137-181. doi: 10.1615/CritRevTherDrugCarrierSyst.2018025649. Crit Rev Ther Drug Carrier Syst. 2019. PMID: 30806211 Review.
-
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.Can J Psychiatry. 2006 Jul;51(8):531-9. doi: 10.1177/070674370605100808. Can J Psychiatry. 2006. PMID: 16933590 Clinical Trial.
-
Withdrawal after substitution of a short-acting for a long-acting benzodiazepine.JAMA. 1983 Nov 25;250(20):2838-40. JAMA. 1983. PMID: 6139491
-
Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.Early Interv Psychiatry. 2020 Feb;14(1):69-79. doi: 10.1111/eip.12826. Epub 2019 May 24. Early Interv Psychiatry. 2020. PMID: 31125513
-
Nonpharmacologic approaches to substance abuse treatment.Med Clin North Am. 1997 Jul;81(4):927-44. doi: 10.1016/s0025-7125(05)70556-3. Med Clin North Am. 1997. PMID: 9222261 Review.
Cited by
-
Drug delivery strategies for the treatment of relapse behavior in substance use disorder- A systematic review.Metab Brain Dis. 2025 Jan 16;40(1):104. doi: 10.1007/s11011-024-01492-8. Metab Brain Dis. 2025. PMID: 39820990
-
Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.Open Forum Infect Dis. 2024 Apr 16;11(4):ofae125. doi: 10.1093/ofid/ofae125. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38628952 Free PMC article.
References
-
- Rehm J, Patra J, Degenhardt L. Psychoactive substance use: Epidemiology and burden of disease. In: Saxena S, Poznyak V, editors. Atlas on Substance Use (2010): Resources for the Prevention and Treatment of Substance Use Disorders. France: World Health Organization; 2010. pp. 7–22.
-
- Fudala PJ, Johnson RE. Alternative Pharmacotherapies for Opioid Addiction. In: Ruiz P, Strain EC, editors. Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. Philadelphia: Lippincott Williams and Wilkins; 2011. pp. 494–500.
-
- Rabinowitz J, Marjefsky S. Predictors of being expelled from and dropping out of alcohol treatment. Psychiatr Serv. 1998;49:187–9. - PubMed
-
- Che Y, Assanangkornchai S, McNeil E, Chongsuvivatwong V, Li J, Geater A, et al. Predictors of early dropout in methadone maintenance treatment program in Yunnan province, China. Drug Alcohol Rev. 2010;29:263–70. - PubMed
-
- Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: A systematic review of the literature. Eur Addict Res. 2012;18:228–45. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources